M. Grivaux, D. Debieuvre, D. Herman, C. Lemonnier, M. J. Crequit et al., Early mortality in lung cancer: French prospective multicentre observational study, Disponible sur, 4818853.
DOI : 10.1016/j.lungcan.2010.03.003

F. Barlesi, J. Mazieres, J. Merlio, D. Debieuvre, J. Mosser et al., Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), The Lancet, vol.387, issue.10026, pp.1415-1441, 2016.
DOI : 10.1016/S0140-6736(16)00004-0

F. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla et al., Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non???Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy, Journal of Clinical Oncology, vol.18, issue.10, pp.2095-103, 2000.
DOI : 10.1200/JCO.2000.18.10.2095

N. Hanna, F. Shepherd, F. Fossella, J. Pereira, D. Marinis et al., Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non???Small-Cell Lung Cancer Previously Treated With Chemotherapy, Journal of Clinical Oncology, vol.22, issue.9, pp.1589-97, 2004.
DOI : 10.1200/JCO.2004.08.163

E. Garon, T. Ciuleanu, O. Arrieta, K. Prabhash, K. Syrigos et al., Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial, The Lancet, vol.384, issue.9944, pp.665-73, 2014.
DOI : 10.1016/S0140-6736(14)60845-X

M. Reck, R. Kaiser, A. Mellemgaard, J. Douillard, S. Orlov et al., Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial, The Lancet Oncology, vol.15, issue.2, pp.143-55, 2014.
DOI : 10.1016/S1470-2045(13)70586-2

F. Shepherd, R. Pereira, J. Ciuleanu, T. Tan, E. Hirsh et al., Erlotinib in Previously Treated Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.353, issue.2, pp.123-155, 2005.
DOI : 10.1056/NEJMoa050753

A. Cortot, C. Audigier-valette, O. Molinier, S. Moulec, F. Barlesi et al., Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from the phase III study IFCT-1103 ULTIMATE, Disponible sur, pp.167643-176, 2017.

D. Chen and I. Mellman, Oncology Meets Immunology: The Cancer-Immunity Cycle, Immunity, vol.39, issue.1, pp.1-10, 2013.
DOI : 10.1016/j.immuni.2013.07.012

S. Pai, D. Zandberg, and S. Strome, The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment, Oral Oncology, vol.61, pp.152-160, 2016.
DOI : 10.1016/j.oraloncology.2016.08.001

N. Rizvi, J. Mazières, D. Planchard, T. Stinchcombe, G. Dy et al., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, The Lancet Oncology, vol.16, issue.3, pp.257-65, 2015.
DOI : 10.1016/S1470-2045(15)70054-9

J. Brahmer, K. Reckamp, P. Baas, L. Crinò, W. Eberhardt et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.2, 2015.
DOI : 10.1056/NEJMoa1504627

H. Borghaei, L. Paz-ares, L. Horn, D. Spigel, M. Steins et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015.
DOI : 10.1056/NEJMoa1507643

S. Peters, F. Cappuzzo, L. Horn, L. Paz-ares, H. Borghaei et al., OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057, Journal of Thoracic Oncology, vol.12, issue.1, p.253, 2017.
DOI : 10.1016/j.jtho.2016.11.241

M. Duruisseaux, I. Rouquette, J. Adam, A. Cortot, A. Cazes et al., Efficacit?? des inhibiteurs du checkpoint immunitaire PD-1/PD-L1??et testing PD-L1??dans les cancers thoraciques, Annales de Pathologie, vol.37, issue.1, pp.61-78, 2017.
DOI : 10.1016/j.annpat.2016.12.009

S. Gettinger, N. Rizvi, L. Chow, H. Borghaei, J. Brahmer et al., Nivolumab Monotherapy for First-Line Treatment of Advanced Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.34, issue.25
DOI : 10.1200/JCO.2016.66.9929

M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-ares et al., NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)???positive NSCLC, Annals of Oncology, vol.27, issue.suppl_6, p.2016, 2017.
DOI : 10.1093/annonc/mdw435.39

M. Reck, D. Rodríguez-abreu, A. Robinson, R. Hui, T. Cs?szi et al., Pembrolizumab versus Chemotherapy for PD-L1???Positive Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016.
DOI : 10.1056/NEJMoa1606774

R. Herbst, J. Soria, M. Kowanetz, G. Fine, O. Hamid et al., Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, vol.9, issue.7528, pp.563-570, 2014.
DOI : 10.1371/journal.pone.0088401

L. Fehrenbacher, A. Spira, M. Ballinger, M. Kowanetz, J. Vansteenkiste et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet, vol.387, issue.10030, 2016.
DOI : 10.1016/S0140-6736(16)00587-0

E. Saada-bouzid, C. Defaucheux, A. Karabajakian, P. Coloma, V. Servois et al., Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors, J Clin Oncol, vol.34, pp.6072-6072, 2016.

S. Champiat, L. Dercle, S. Ammari, C. Massard, A. Hollebecque et al., Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1, Clinical Cancer Research, vol.23, issue.8, 2017.
DOI : 10.1158/1078-0432.CCR-16-1741

G. Leprieur, E. Dumenil, C. , J. C. Giraud, V. Dumoulin et al., Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges, European Journal of Cancer, vol.78, pp.16-23, 1990.
DOI : 10.1016/j.ejca.2016.12.041

J. Mclaughlin, G. Han, K. Schalper, D. Carvajal-hausdorf, V. Pelekanou et al., Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non???Small-Cell Lung Cancer, JAMA Oncology, vol.2, issue.1, pp.46-54, 2016.
DOI : 10.1001/jamaoncol.2015.3638

M. Ilie, E. Long-mira, C. Bence, C. Butori, S. Lassalle et al., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, Annals of Oncology, vol.27, issue.1, pp.147-53, 2016.
DOI : 10.1093/annonc/mdv489

S. Kitazono, Y. Fujiwara, K. Tsuta, H. Utsumi, S. Kanda et al., Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non???Small-Cell Lung Cancer, Clinical Lung Cancer, vol.16, issue.5, pp.385-90, 2015.
DOI : 10.1016/j.cllc.2015.03.008

H. Uruga, E. Bozkurtlar, T. Huynh, A. Muzikansky, Y. Goto et al., Programmed Cell Death Ligand (PD-L1) Expression in??Stage II and III Lung Adenocarcinomas and Nodal??Metastases, Journal of Thoracic Oncology, vol.12, issue.3, pp.458-66, 2017.
DOI : 10.1016/j.jtho.2016.10.015

M. Callea, L. Albiges, M. Gupta, S. Cheng, E. Genega et al., Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma, Cancer Immunology Research, vol.3, issue.10, pp.1158-64, 2015.
DOI : 10.1158/2326-6066.CIR-15-0043

L. Bracci, G. Schiavoni, A. Sistigu, and F. Belardelli, Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer, Cell Death and Differentiation, vol.118, issue.1, pp.15-25, 2014.
DOI : 10.1172/JCI34333

S. Ngiow, G. Mcarthur, and M. Smyth, Radiotherapy complements immune checkpoint blockade. Cancer Cell. 13 avr 2015, pp.437-445

E. Garon, N. Rizvi, R. Hui, N. Leighl, A. Balmanoukian et al., Pembrolizumab for the Treatment of Non???Small-Cell Lung Cancer, New England Journal of Medicine, vol.372, issue.21, 2015.
DOI : 10.1056/NEJMoa1501824

M. Ilie, V. Hofman, M. Dietel, J. Soria, and P. Hofman, Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients, Virchows Archiv, vol.20, issue.Suppl 3, pp.511-536, 2016.
DOI : 10.1158/1078-0432.CCR-14-0933

J. Adam, D. Planchard, A. Marabelle, J. Soria, J. Scoazec et al., ??valuation de l???expression de PD-L1 en immunohistochimie??: un biomarqueur ??mergent dans les carcinomes pulmonaires non ?? petites cellules, Annales de Pathologie, vol.36, issue.1, pp.94-102, 2016.
DOI : 10.1016/j.annpat.2015.11.004

K. Mahoney, H. Sun, X. Liao, P. Hua, M. Callea et al., PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells, Cancer Immunology Research, vol.3, issue.12, pp.1308-1323, 2015.
DOI : 10.1158/2326-6066.CIR-15-0116

S. Patel and R. Kurzrock, PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy, Molecular Cancer Therapeutics, vol.14, issue.4, pp.847-56, 2015.
DOI : 10.1158/1535-7163.MCT-14-0983

V. Hofman, M. Ilie, E. Long, C. Butori, S. Lassalle et al., Enjeux et limites actuelles de l?????valuation du statut de PD-L1??par immunohistochimie sur des biopsies bronchiques, Bulletin du Cancer, vol.103, issue.4, pp.368-80, 2016.
DOI : 10.1016/j.bulcan.2016.01.014

M. Ratcliffe, A. Sharpe, A. Midha, C. Barker, M. Scott et al., Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non???Small Cell Lung Cancer, Clinical Cancer Research, vol.23, issue.14, 2017.
DOI : 10.1158/1078-0432.CCR-16-2375

A. Scheel, M. Dietel, L. Heukamp, K. Jöhrens, T. Kirchner et al., Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas, Modern Pathology, vol.85, issue.10, pp.1165-72, 2016.
DOI : 10.1200/JCO.2014.58.1041

F. Hirsch, A. Mcelhinny, D. Stanforth, J. Ranger-moore, M. Jansson et al., PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project, Journal of Thoracic Oncology, vol.12, issue.2, pp.208-230, 2017.
DOI : 10.1016/j.jtho.2016.11.2228

J. Cogswell, H. Inzunza, Q. Wu, J. Feder, G. Mintier et al., An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1, Molecular Diagnosis & Therapy, vol.23, issue.Suppl 1, pp.85-93, 2017.
DOI : 10.1097/PAI.0000000000000256

D. Rimm, G. Han, J. Taube, E. Yi, J. Bridge et al., Multiinstitutional , Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD- L1 Expression in Non?Small Cell Lung Cancer, Disponible sur, p.2017, 2017.

K. Schats, V. Vré, E. , D. Schepper, S. Boeckx et al., Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system, Histopathology, vol.1, issue.Suppl. 2, pp.253-63, 2017.
DOI : 10.1080/23808993.2016.1140005

V. Velcheti, K. Schalper, D. Carvajal, V. Anagnostou, K. Syrigos et al., Programmed death ligand-1 expression in non-small cell lung cancer, Laboratory Investigation, vol.0959, issue.8049, pp.107-123, 2014.
DOI : 10.1126/scitranslmed.3006504

F. Passiglia, G. Bronte, V. Bazan, C. Natoli, S. Rizzo et al., PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis, Oncotarget, vol.7, issue.15, pp.19738-19785, 2016.
DOI : 10.18632/oncotarget.7582

O. Abdel-rahman, Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis, Critical Reviews in Oncology/Hematology, vol.101, pp.75-85, 2016.
DOI : 10.1016/j.critrevonc.2016.03.007

P. Aguiar, I. Santoro, H. Tadokoro, G. De-lima-lopes, B. Filardi et al., The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis, Immunotherapy, vol.33, issue.3, pp.479-88, 2016.
DOI : 10.1056/NEJMoa1200690

D. Incecco, A. Andreozzi, M. Ludovini, V. Rossi, E. Capodanno et al., PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients, British Journal of Cancer, vol.49, issue.1, pp.95-102, 2015.
DOI : 10.1038/nri2326

J. Wolchok, A. Hoos, O. Day, S. Weber, J. Hamid et al., Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, Clinical Cancer Research, vol.15, issue.23, pp.7412-7432, 2009.
DOI : 10.1158/1078-0432.CCR-09-1624

V. Anagnostou, K. Smith, P. Forde, N. Niknafs, R. Bhattacharya et al., Evolution of Neoantigen Landscape During Immune Checkpoint Blockade in Non-Small Cell Lung Cancer, Cancer Discov. 1 janv, pp.16-0828, 2017.

J. Dunn and S. Rao, Epigenetics and immunotherapy: The current state of play, Molecular Immunology, vol.87, pp.227-266, 2017.
DOI : 10.1016/j.molimm.2017.04.012

M. Maio, A. Covre, E. Fratta, D. Giacomo, A. Taverna et al., Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy, Clinical Cancer Research, vol.21, issue.18, pp.4040-4047, 2015.
DOI : 10.1158/1078-0432.CCR-14-2914

Y. Liu, Y. Komohara, N. Domenick, M. Ohno, M. Ikeura et al., Expression of antigen processing and presenting molecules in brain metastasis of breast cancer, Cancer Immunology, Immunotherapy, vol.128, issue.2, pp.789-801, 2012.
DOI : 10.1002/ijc.25613

A. Qin, D. Coffey, E. Warren, and N. Ramnath, Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer, Cancer Medicine, vol.33, issue.10027, 2016.
DOI : 10.1148/rg.352140121

J. Schoenhals, S. Seyedin, C. Anderson, E. Brooks, Y. Li et al., Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation, Translational Lung Cancer Research, vol.6, issue.2, pp.148-58, 2017.
DOI : 10.21037/tlcr.2017.03.06

T. Gajewski, H. Schreiber, and Y. Fu, Innate and adaptive immune cells in the tumor microenvironment, Nature Immunology, vol.179, issue.10, pp.1014-1036, 2013.
DOI : 10.1016/j.ijrobp.2012.12.025

M. Neurath and S. Finotto, The emerging role of T cell cytokines in non-small cell lung cancer, Cytokine & Growth Factor Reviews, vol.23, issue.6, pp.315-337, 2012.
DOI : 10.1016/j.cytogfr.2012.08.009

Y. Shigematsu, T. Hanagiri, H. Shiota, K. Kuroda, T. Baba et al., Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes, Oncol Lett. oct, vol.4, issue.4, pp.625-655, 2012.

R. Petersen, M. Campa, J. Sperlazza, D. Conlon, M. Joshi et al., Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients, Cancer, vol.310, issue.12, pp.2866-72, 2006.
DOI : 10.1159/000386035

X. Zhuang, X. Xia, C. Wang, F. Gao, N. Shan et al., A High Number of CD8+ T Cells Infiltrated in NSCLC Tissues is Associated With a Favorable Prognosis, Applied Immunohistochemistry & Molecular Morphology, vol.18, issue.1, pp.24-32, 2010.
DOI : 10.1097/PAI.0b013e3181b6a741

L. Bingle, N. Brown, and C. Lewis, The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies, The Journal of Pathology, vol.7, issue.3, pp.254-65, 2002.
DOI : 10.1038/sj.gt.3301058

A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy, European Journal of Cancer, vol.42, issue.6, pp.717-744, 1990.
DOI : 10.1016/j.ejca.2006.01.003

A. Kataki, P. Scheid, M. Piet, M. B. Martinet, N. Martinet et al., Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression, Journal of Laboratory and Clinical Medicine, vol.140, issue.5, pp.320-328, 2002.
DOI : 10.1067/mlc.2002.128317

P. Korkolopoulou, L. Kaklamanis, F. Pezzella, A. Harris, and K. Gatter, Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer, British Journal of Cancer, vol.73, issue.2, pp.148-53, 1996.
DOI : 10.1038/bjc.1996.28

S. Derniame, J. Vignaud, G. Faure, and M. Béné, Alteration of the immunological synapse in lung cancer: a microenvironmental approach, Clinical & Experimental Immunology, vol.288, issue.1, pp.48-55, 2008.
DOI : 10.1164/ajrccm/139.2.330

F. Garrido, F. Perea, M. Bernal, A. Sánchez-palencia, N. Aptsiauri et al., The Escape of Cancer from T Cell-Mediated Immune Surveillance: HLA Class I Loss and Tumor Tissue Architecture, Vaccines, vol.256, issue.1, p.7, 2017.
DOI : 10.1016/S0074-7696(07)56005-5

S. Nagaraj, K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman et al., Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer, Nature Medicine, vol.166, issue.7, pp.828-863, 2007.
DOI : 10.4049/jimmunol.166.9.5398

F. Perea, M. Bernal, A. Sánchez-palencia, J. Carretero, C. Torres et al., The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration, International Journal of Cancer, vol.375, issue.4, pp.888-99, 2017.
DOI : 10.1056/NEJMoa1604958

K. Bardhan, T. Anagnostou, and V. Boussiotis, The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation, Frontiers in Immunology, vol.4, issue.12, 5149523.
DOI : 10.1186/s40425-016-0118-0

D. Pardoll, The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, vol.12, issue.4, pp.252-64, 2012.
DOI : 10.1038/nrc3237

H. Arasanz, M. Gato-cañas, M. Zuazo, M. Ibañez-vea, K. Breckpot et al., PD1 signal transduction pathways in T cells, Oncotarget, vol.5, issue.0, 2017.
DOI : 10.18632/oncotarget.17232

M. Butte, M. Keir, T. Phamduy, A. Sharpe, and G. Freeman, Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses, Immunity, vol.27, issue.1, pp.111-133, 2007.
DOI : 10.1016/j.immuni.2007.05.016

M. Marzec, Q. Zhang, A. Goradia, P. Raghunath, X. Liu et al., Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1), Proceedings of the National Academy of Sciences, vol.179, issue.5, pp.20852-20859, 2008.
DOI : 10.4049/jimmunol.179.5.2860

J. Taube, R. Anders, G. Young, H. Xu, R. Sharma et al., Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, Science Translational Medicine, vol.27, issue.36, pp.127-164, 2012.
DOI : 10.1200/JCO.2009.23.4799

S. Spranger, R. Spaapen, Y. Zha, J. Williams, Y. Meng et al., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

J. He, Y. Hu, M. Hu, and B. Li, Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non, Small Cell Lung Cancer. Sci Rep. 17 août, vol.5, p.13110, 2015.

L. Strauss, T. Whiteside, A. Knights, C. Bergmann, A. Knuth et al., Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin, The Journal of Immunology, vol.178, issue.1, pp.320-329, 2007.
DOI : 10.4049/jimmunol.178.1.320

L. Francisco, P. Sage, and A. Sharpe, The PD-1 pathway in tolerance and autoimmunity, Immunological Reviews, vol.183, issue.1, pp.219-261, 2010.
DOI : 10.4049/jimmunol.176.5.3000

R. Michalek, V. Gerriets, S. Jacobs, A. Macintyre, N. Maciver et al., Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets, The Journal of Immunology, vol.186, issue.6, pp.3299-303, 1950.
DOI : 10.4049/jimmunol.1003613

V. Rosa, F. Rella, A. Giacomo, and G. Matarese, Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism, Cytokine & Growth Factor Reviews, vol.35, pp.15-25, 2017.
DOI : 10.1016/j.cytogfr.2017.04.001

V. Huber, C. Camisaschi, A. Berzi, S. Ferro, L. Lugini et al., Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation, Seminars in Cancer Biology, vol.43, pp.74-89, 2017.
DOI : 10.1016/j.semcancer.2017.03.001